The Gene Therapy Superhighway
Gene Therapy companies need delivery devices for their therapies and device companies must increasingly embrace biotechnologies to improve and differentiate their increasingly commoditized offerings. In a handful of device/biotech deals signed in the pas year, device companies are gaining exclusive worldwide rights to new cardiovascular gene therapies. The next meeting ground for gene therapies and devices: orthobiologics.
You may also be interested in...
Despite the millions of dollars from public initiatives, particularly in California, to fund stem-cell research, VCs will still probably stay away until Big Pharma and Big Biotech show more of their own R&D interest in the area.
Pharma is looking to GAVI to oversee a fair distribution and avoid ‘vaccine nationalism’ – but countries can still sign bilateral deals with companies.
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.